Activities of advertising agencies
IMMUNOPHARMA AS
Revenue 2024
NOK 12.2m
Operating profit
NOK −38.5m
Equity
NOK 209.0m
Incorporated
2009
Employees
13
Share capital
NOK 13.9m
Key figures · 2024
Current ratio
0.56
Equity ratio
61.8%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -315.6% | |
| Net margin (%%) | 112.4% | |
| Return on assets (%%) | -11.4% | |
| Likviditet | ||
| Current ratio | 0.56 | |
| Working capital | −56.0m | |
| Soliditet | ||
| Equity ratio (%%) | 61.8% | |
| Debt-to-equity ratio | 0.62 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.